Stocks Amgen Inc

More

  • graphic_word_ofthe_street.jpg

    The Dow closed lower on Friday after General Motors reported hefty losses and new data showed U.S. employers cut jobs for the seventh straight month.

  • The markets end the week roughly flat as an increase in oil prices and the highest unemployment rate since March 2004 weighed on stocks, but Financials rallied.

  • What a crazy week, right? Monday, Amgen had a huge upside revenue and earnings surprise. Tuesday, the Food and Drug Administration issued its new restrictions on the use of Amgen's anemia drugs in certain cancer patients. Later that same day, Elan and Wyeth released the big Alzheimer's drug test results.

  • It just goes to show you, a little attitude never hurts: Stocks clawed back all of the prior session's losses as oil hit its lowest point since May and consumer confidence improved.

  • It's all in the attitude today: Stocks rose after an improvement in consumer confidence.  Stocks were already pointing higher as oil prices receded but that little shot of confidence pushed the Dow up to a triple-digit gain.

  • It's all in the attitude today: Stocks rose after an improvement in consumer confidence.  Stocks were already pointing higher as oil prices receded but that little shot of confidence pushed the Dow up to a triple-digit gain.

  • Two strategists, Stephen Wood at Russell Investments and John Manley at Citi Smith Barney, shared their market rebound strategies with CNBC.

  • graphic_word_ofthe_street.jpg

    The Dow tumbled on Monday as more credit and housing market turmoil battered financial shares.

  • Amgen

    Amgen reported a profit and sales that climbed higher and beat analysts' forecasts as sales of two key drugs topped expectations.

  • Stocks declined Monday, led by financials after two more banks folded. Oil ticked higher after three straight weeks of decline, clipping consumer-discretionary stocks, including homebuilders, airlines and retailers.

  • Merrill Lynch, Amgen, and some medical instrument outfits are getting a lot of options action this week, according to one observer.

  • graphic_fast_money.jpg

    Pete Najarian reveals 3 biotechs he feels provide the most bang for the buck?

  • Stocks declined Monday, led by financials after two more banks folded. Oil ticked higher after three straight weeks of decline.

  • Stocks were mixed Monday as banks rallied and oil gained more than $1 a barrel.

  • Shares of Amgen surged after the company reported positive trial results for its osteoporosis drug candidate denosumab—which one analyst terms "a future blockbuster."

  • AMGEN

    Amgen surprised the market late on a summer Friday by announcing positive test results from the big, crucial study of its experimental osteoporosis drug. The stock shot up after hours and continues to rally this morning.

  • In the last month healthcare has emerged as the best performing sector in the S&P. Are drug makers a cure for your portfolio in this economic downturn?

  • An analyst predicts that gold will head into a bull market, and Washington Mutual increases its liquidity position. The following are today's top videos:

  • Amgen shares leaped in late trading Friday after the company said a pivotal trial of its experimental osteoporosis drug denosumab met its goal of significantly reducing the risk of bone fracture in post-menopausal women.

  • To give investors an edge, CNBC asked the market experts for their best trades now.